非布司他使用说明

It is suitable for the long-term treatment of hyperuricemia in patients with gout, but is not recommended for asymptomatic hyperuricemia. Although febuxostat has been on the market for some time, there are still patients who don’t quite understand its instructions for use. Let’s take a look!

Instructions for use of Febuxostat:

1. Febuxostat tablets are ordinary film-coated tablets, which are gastric-soluble tablets and can be taken in separate pieces.

2. The recommended starting dose of Febuxostat tablets is 40 mg, once a day. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 µmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day.

3. When administering the drug, there is no need to consider the effects of food and antacids.

4. Reducing blood uric acid to below 360 μmol/L can control the condition, promote the dissolution of existing tophi, and prevent the occurrence of kidney disease.

5. Fluctuations in blood uric acid levels can easily induce acute attacks of gout.

Febuxostat can quickly reduce blood uric acid levels, and in the early stages of medication, the probability of causing an acute gout attack is greater than that of allopurinol. Therefore, the recommended initial dose of febuxostat is 20 to 40 mg once daily.

To prevent gout attacks during the initial stage of taking febuxostat, it is recommended to take nonsteroidal anti-inflammatory drugs (50% of the regular dose) or colchicine (0.5~1mg/day) at the same time. Preventive treatment is maintained for 3 to 6 months, and is adjusted according to the patient's gouty arthritis attack.

If gout attacks during treatment with febuxostat, there is no need to interrupt the medication.

6. Special groups

Patients with hepatic insufficiency: Patients with mild or moderate hepatic insufficiency (Child-Pugh Class A, B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh Class C) should use febuxostat with caution.

Renal Impairment: No dose adjustment is required for patients with mild or moderate renal impairment. There are insufficient study data in patients with severe renal impairment, so febuxostat should be used with caution in these patients.

Febuxostat is eliminated via hepatic and renal pathways. About 49% is excreted through urine and about 45% is excreted through feces. The average terminal elimination half-life is approximately 5 to 8 hours.